All In Biotech

Drug Trial Radar · NCT06228053

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

53

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Syntrix Biosystems, Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • SX-682Drug

    Specified dose twice daily

  • EnzalutamideDrug

    Specified dose once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical BenefitTime frame: Ten 21-day treatment cycles

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Not yet recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.